The study was conducted to describe the results of BT-A treatment on idiopathic blepharospasm. In 60 patients, 75 percent of patients are in stage III and 25 percent of patients in stage IV. the authors did bilateral BT-A injections to 60 patients with the initial dose is 5U/1 the injection site. Injection amount depended on individual status. Medication started to be effective after 1 - 10 days, reached the maximum after 7 to 10 days and went off after 3 months. After injection, decreased blepharospasm stage was noticed with 95 percent patients. 45 percent of these had a complete recovery to stage 0 with wide open eyes. Side effects could be cited as 30 percent ptosis, 28 percent dry eyes and 33.3 percent watery eyes. These can appear 2 - 7 days after injection and disappeared in 1 - 6 weeks. BT-A was concluded to be safe, effective with transient mild side effects.